Home » Stocks » HGEN

Humanigen Inc. (HGEN)

Stock Price: $9.54 USD 0.58 (6.47%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $9.35 -0.19 (-1.99%) Nov 27, 4:02 PM

Stock Price Chart

Key Info

Market Cap 492.42M
Revenue (ttm) n/a
Net Income (ttm) -59.27M
Shares Out 51.62M
EPS (ttm) -2.00
PE Ratio n/a
Forward PE 2.19
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $9.54
Previous Close $8.96
Change ($) 0.58
Change (%) 6.47%
Day's Open 9.17
Day's Range 9.01 - 9.60
Day's Volume 340,749
52-Week Range 1.50 - 33.95

More Stats

Market Cap 492.42M
Enterprise Value 400.92M
Earnings Date (est) Mar 30, 2021
Ex-Dividend Date n/a
Shares Outstanding 51.62M
Float 41.26M
EPS (basic) -1.71
EPS (diluted) -2.00
FCF / Share -1.07
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 719,497
Short Ratio 1.74
Short % of Float 1.74%
Beta -0.78
PE Ratio n/a
Forward PE 2.19
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 15.12
Revenue n/a
Operating Income -57.58M
Net Income -59.27M
Free Cash Flow -46.71M
Net Cash 91.50M
Net Cash / Share 1.77
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -77.62%
ROE -183.48%
ROIC 589.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$28.50*
(198.74% upside)
Low
25.0
Current: $9.54
High
34.0
Target: 28.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue------0.046.1020.2617.71
Revenue Growth-------99.28%-69.89%14.36%-
Gross Profit------0.046.1020.2617.71
Operating Income-8.94-11.48-19.03-27.01-34.35-36.72-40.91-23.48-2.27-6.12
Net Income-10.29-12.00-21.99-27.02-35.38-38.00-41.95-23.51-2.23-5.10
Shares Outstanding22.3618.953.001.940.830.820.610.050.050.04
Earnings Per Share-0.45-0.65-7.35-13.90-42.85-46.10-69.20-448.80-46.00-120.80
Operating Cash Flow-4.00-6.21-14.25-20.96-29.06-35.94-38.82-23.91-15.3314.40
Capital Expenditures---0.01-0.02-0.45-0.340.15-0.46-0.07
Free Cash Flow-4.00-6.21-14.25-20.95-29.08-36.39-39.16-23.76-15.7914.33
Cash & Equivalents0.210.890.843.018.6240.9176.9420.5018.0534.24
Total Debt6.493.5019.374.295.4110.939.979.83--
Net Cash / Debt-6.27-2.61-18.53-1.283.2129.9866.9710.6818.0534.24
Assets0.521.371.674.7211.1542.9878.7024.5419.3535.98
Liabilities14.849.4826.019.105.4118.3618.1717.468.5123.21
Book Value-14.32-8.11-24.34-4.385.7324.6160.54-94.94-72.35-70.40
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Humanigen Inc.
Country United States
Employees 2
CEO Cameron Durrant

Stock Information

Ticker Symbol HGEN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: HGEN
IPO Date January 31, 2013

Description

Humanigen, a clinical stage biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase Ib/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. It also develops Ifabotuzumab, a monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005 an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic diseases. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.